<DOC>
	<DOCNO>NCT00545090</DOCNO>
	<brief_summary>This single arm study continue drug safety surveillance , assessment adherence , patient postmenopausal osteoporosis receive monthly oral Bonviva ML19930 , BonAdAsia study . All patient complete 6 month ML19930 continue receive Bonviva ( 150mg po , monthly ) additional 6 month . The anticipated time study treatment 3-12 month , target sample size 500+ individual .</brief_summary>
	<brief_title>ExBonAdAsia Study : A Study Once Monthly Bonviva ( Ibandronate ) Women With Post-Menopausal Osteoporosis .</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Ibandronic acid</mesh_term>
	<criteria>patient respond oral monthly Bonviva BonAdAsia study ; willing continue Bonviva treatment 6 month . none specify .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>